[go: up one dir, main page]

WO2002014306A1 - Process for the preparation of imidazopyridines - Google Patents

Process for the preparation of imidazopyridines Download PDF

Info

Publication number
WO2002014306A1
WO2002014306A1 PCT/EP2000/008021 EP0008021W WO0214306A1 WO 2002014306 A1 WO2002014306 A1 WO 2002014306A1 EP 0008021 W EP0008021 W EP 0008021W WO 0214306 A1 WO0214306 A1 WO 0214306A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
hydrogen
halogen
denote
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/008021
Other languages
French (fr)
Inventor
Max Rey
Armin RÖSSLER
Giusep Derungs
Jae-Kyoung Pak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag AG
Original Assignee
Cilag AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag AG filed Critical Cilag AG
Priority to AU2000264428A priority Critical patent/AU2000264428A1/en
Priority to PCT/EP2000/008021 priority patent/WO2002014306A1/en
Priority to JP2002519456A priority patent/JP2004506634A/en
Priority to DE60102478T priority patent/DE60102478D1/en
Priority to EP01980251A priority patent/EP1311509B1/en
Priority to SK101-2003A priority patent/SK1012003A3/en
Priority to CZ2003321A priority patent/CZ294416B6/en
Priority to AU2002212143A priority patent/AU2002212143A1/en
Priority to US10/344,713 priority patent/US6841679B2/en
Priority to PCT/EP2001/009519 priority patent/WO2002014316A1/en
Priority to CA002417821A priority patent/CA2417821A1/en
Priority to AT01980251T priority patent/ATE262526T1/en
Publication of WO2002014306A1 publication Critical patent/WO2002014306A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Definitions

  • the present invention relates to a process for preparing imidazopyridin s of the general formula (1)
  • Y denotes hydrogen, a halogen or a C _ 4 alkyl group
  • X x and X 2 denote, independently of each other, hydrogen, a halogen or a C x _ 4 alkoxy, C _ 6 alkyl, CF 3 , CH 3 S, CH 3 S0 2 or N0 2 group and
  • R x and R 2 denote, independently of each other, hydrogen or a C 1 _ s alkyl group, with the proviso that R x and R 2 do not both denote hydrogen, or salts thereof.
  • the present invention relates to a more efficient process for preparing compounds of formula (1) .
  • compounds of the general formula (1) can be prepared by reacting a compound of the general formula (2) in which Y, X x and X 2 , are as defined above with a compound of the general formula (3)
  • A denotes a halogen and B denotes a halogen, a C x _ 4 alkoxy group or an NR X R 2 group in which R and R 2 are as defined above to form a compound of the general formula (4)
  • R x and R 2 are as defined above to form a compound of the general formula (6) in which Y, X l t X 2 , R x and R 2 are as defined above.
  • the compound of formula (6) can be treated with a reducing agent If desired, the compound of formula (1) thus obtained is converted into a salt .
  • compound (6) is prepared by reacting an imidazopyridine of formula (2) with an oxalic acid derivative of formula (3) .
  • This reaction is conveniently carried out in an aprotic organic solvent, for example n- hexane, cyclohexane, acetonitrile, acetone, ethylacetate, toluene, methyl tert. butyl ether or mixtures of these solvents, preferably a mixture of cyclohexane with toluene, at a temperature range from 0-100° C, preferably from 0- 10°C, and in the presence of an organic base, for example tertiary alkylamines, pyridine or substituted pyridines, preferably pyridine.
  • an organic base for example tertiary alkylamines, pyridine or substituted pyridines, preferably pyridine.
  • formula (3) B denotes a halogen or a C 1 . 4 alkoxy group
  • the product (4) thus obtained is subsequently reacted with a primary or secondary amine of formula (5) , conveniently at a temperature range from 0- 100°C, preferably from 30-40°C.
  • formula (3) B denotes an NR X R 2 group
  • the reaction of compound (2) with compound (3) directly yields a compound of formula (6) instead of compound (4) , and no intervening treatment with a compound of formula (5) is necessary.
  • the compound of formula (6) thus obtained is then reacted with an appropriate reducing agent to form compound (1) .
  • This reaction is conveniently carried out in a polar aprotic solvent, for example pyridine, dimethylformamide or acetonitrile, preferably pyridine, in the presence of an organic acid, for example acetic acid, formic acid or toluenesulfonic acid, preferably acetic acid, and of an acylating agent, for example acetic anhydride or acetylchloride, preferably acetic anhydride, at a temperature range from 25-75°C, preferably from 50-55°C.
  • a suitable reducing agent is, for example, Zn.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of general formula (1), in which Y denotes hydrogen, a halogen or a C1-4 alkyl group X1 and X2 denote, independently of each other, hydrogen, a halogen or a C1-4 alkoxy, C1-6 alkyl, CF3, CH3S CH3SO2 or NO2 group and R1 and R2 denote independently of each other, hydrogen or a C1-5 alkyl group, with the proviso that R1 and R2 do not both denote hydrogen, or a salt thereof is prepared by a multi-step process, the last step of which comprises reducing a compound of general formula (6), in which Y, X1, X2, R1 and R2 are as defined above with an appropriate reducing agent, such as Zn, and, if desired, converting the compound of formula (1) thus obtained, into a salt. The product of this process are known to have useful pharmacological properties, e.g. as anxiolytics.

Description

PROCESS FOR THE PREPARATION OF I IDAZOPYRIDINES
The present invention relates to a process for preparing imidazopyridin s of the general formula (1)
Figure imgf000002_0001
in which:
Y denotes hydrogen, a halogen or a C _4 alkyl group,
Xx and X2 denote, independently of each other, hydrogen, a halogen or a Cx_4 alkoxy, C _6 alkyl, CF3, CH3S, CH3S02 or N02 group and
Rx and R2 denote, independently of each other, hydrogen or a C1_s alkyl group, with the proviso that Rx and R2 do not both denote hydrogen, or salts thereof.
The products of this process are known to have useful pharmacological properties, e.g. as anxiolytics, see European Patent No. 0 050 563. A process for preparing compounds of formula 1 is described in US Patent No. 4,794,185, Dec. 12, 1988.
The present invention relates to a more efficient process for preparing compounds of formula (1) .
In accordance with the present invention, compounds of the general formula (1) can be prepared by reacting a compound of the general formula (2)
Figure imgf000003_0001
in which Y, Xx and X2, are as defined above with a compound of the general formula (3)
Figure imgf000003_0002
in which:
A denotes a halogen and B denotes a halogen, a Cx_4 alkoxy group or an NRXR 2 group in which R and R2 are as defined above to form a compound of the general formula (4)
Figure imgf000003_0003
in which Y, Xx, X2 and B are as defined above, and, if B denotes a halogen or a Cx.4 alkoxy group, reacting the compound of the general formula (4) with a compound of the general formula (5)
Figure imgf000003_0004
in which Rx and R2 are as defined above to form a compound of the general formula (6)
Figure imgf000004_0001
in which Y, Xl t X2, Rx and R2 are as defined above.
To form a compound of formula (1) , the compound of formula (6) can be treated with a reducing agent If desired, the compound of formula (1) thus obtained is converted into a salt .
It will be appreciated that if in formula (3) B denotes an NRXR 2 group in which R1 and R2 are as defined above, compound (6) instead of compound (4) is formed directly by reaction of compound (2) with compound (3) .
As set forth above compound (6) is prepared by reacting an imidazopyridine of formula (2) with an oxalic acid derivative of formula (3) . This reaction is conveniently carried out in an aprotic organic solvent, for example n- hexane, cyclohexane, acetonitrile, acetone, ethylacetate, toluene, methyl tert. butyl ether or mixtures of these solvents, preferably a mixture of cyclohexane with toluene, at a temperature range from 0-100° C, preferably from 0- 10°C, and in the presence of an organic base, for example tertiary alkylamines, pyridine or substituted pyridines, preferably pyridine. If in formula (3) B denotes a halogen or a C1.4 alkoxy group, the product (4) thus obtained is subsequently reacted with a primary or secondary amine of formula (5) , conveniently at a temperature range from 0- 100°C, preferably from 30-40°C. If in formula (3) B denotes an NRXR2 group, the reaction of compound (2) with compound (3) directly yields a compound of formula (6) instead of compound (4) , and no intervening treatment with a compound of formula (5) is necessary. The compound of formula (6) thus obtained is then reacted with an appropriate reducing agent to form compound (1) . This reaction is conveniently carried out in a polar aprotic solvent, for example pyridine, dimethylformamide or acetonitrile, preferably pyridine, in the presence of an organic acid, for example acetic acid, formic acid or toluenesulfonic acid, preferably acetic acid, and of an acylating agent, for example acetic anhydride or acetylchloride, preferably acetic anhydride, at a temperature range from 25-75°C, preferably from 50-55°C. A suitable reducing agent is, for example, Zn.
The compounds of the general formula (6) and their preparation also form part of the present invention.
The following examples illustrate the invention in greater detail .
EXAMPLE 1
Preparation of 6-methyl-N,N-dimethyl-2- (4- methylphenyl) imidazo [1, 2-a]pyridine-3-glyoxyacetamide, compound (6)
To a slurry of 10.0 g (45 mmol) of 6-methyl-N,N-dimethyl-2- (4-methylphenyl) imidazo [1, 2-a] pyridine in a mixture of 20.0 g of toluene and 28.0 g of cyclohexane were added 8.6 (0.068 mmol) of oxalylchloride within 15 minutes at 0-5°C. 3.6 g (45 mmol) of pyridine were added within 5 minutes at 0-5°C. The resulting slurry was heated to 65-70°C and stirred for 2 hours. Then it was cooled to 30-35°C and 8.4 g (187 mmol) of dimethylamine were introduced. To the slurry were added 26.0 g of water and 2.3 g of isopropanol . The product was isolated by filtration to afford the title compound in 80 % yield. EXAMPLE 2
Preparation of N,N-dimethyl-2- [6-methyl-2- (4- methylphenyl) imidazo [1, 2-a] pyridine-3-yl] acetamide, compound (1)
To a slurry of 150.0 g (0.467 mol) of 6-methyl-N,N- dimethyl-2- (4-methylphenyl) imidazo [1, 2-a] yridine-3 - glyoxyacetamide and 105.0 g (1.605 mol) of zinc powder in 443.0 g of pyridine was added a solution of 94.0 g (0.920 mol) of acetic anhydride in 472.5 g of acetic acid within 20 - 25 minutes at a temperature below 45°C. The suspension was then heated to 50-55°C and stirred for 25-30 hours. Unreacted zinc was filtered off and the filtrate was subjected to a vacuum distillation. To the remaining oil 455.0 g of 25% aqueous ammonia solution were added. The precipitated solid was collected by filtration and purified by recrystallization in 800.0 g of methylisobutylketone . The title compound was afforded in 65.6 % yield.

Claims

CLAIMS :
1. A process for preparing compounds of the general formula (6)
Figure imgf000007_0001
in which:
Y denotes hydrogen, a halogen or a C^ alkyl group x and X2 denote, independently of each other, hydrogen, a halogen or a Cx_4 alkoxy, ^ alkyl, CF3, CH3S, CH3S02 or N02 group and
R and R2 denote, independently of each other, hydrogen or a C-L.5 alkyl group, with the proviso that R and R2 do not both denote hydrogen,
which process comprises reacting a compound of the general formula (2)
Figure imgf000007_0002
in which Y, Xx and X2, are as defined above with a compound of the general formula (3)
(3)
V
in which: A denotes a halogen and B denotes a halogen, a Cx.4 alkoxy group or an NRXR 2 group in which Rx and R2 are as defined above to form a compound of the general formula (4)
Figure imgf000008_0001
in which Y, Xx X2 and B are as defined above and, if B denotes a halogen or a Cα_4 alkoxy group, reacting the compound of formula (4) with a compound of the general formula (5)
r
H—N<^ (5)
R2
in which Rx and R2 are as defined above
2. A compound of the general formula (6)
Figure imgf000008_0002
in which:
Y denotes hydrogen, a halogen or a C^ alkyl group
X and X2 denote, independently of each other, hydrogen, a halogen or a C^ alkoxy, C _β alkyl, CF3, CH3S, CH3S02 or N02 group and R1 and R2 denote independently of each other, hydrogen or a C .s alkyl group, with the proviso that R and R2 do not both denote hydrogen.
3. A process for preparing a compound of the general formula (1)
Figure imgf000009_0001
in which:
Y denotes hydrogen, a halogen or a Cx.4 alkyl group
Xx and X2 denote, independently of each other, hydrogen, a halogen or a Cx_4 alkoxy, Cx.ε alkyl, CP3, CH3S CH3S02 or N02 group and
R± and R2 denote independently of each other, hydrogen or a
Ci-s alkyl group, with the proviso that R1 and R2 do not both denote hydrogen, or a salt thereof which process comprises reducing a compound of the general formula (6)
Figure imgf000009_0002
in which Y, X17 X2, Rx and R2 are as defined above with an appropiate reducing agent and, if desired, converting the compound of formula (1) thus obtained into a salt .
4. A process according to claim 3 wherein the reducing agent is Zn .
5. A process according to claim 3 or claim 4 wherein the reduction is carried out in pyridine, dimethylformamide, dimethylacetamide, acetonitrile or a derivative of any of these, in the presence of acetic acid, formic acid or toluenesulfonic acid and of an acylating agent .
6. A process according to claim 5 wherein the acylating agent is acetic anhydride or acetylchloride .
PCT/EP2000/008021 2000-08-17 2000-08-17 Process for the preparation of imidazopyridines Ceased WO2002014306A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2000264428A AU2000264428A1 (en) 2000-08-17 2000-08-17 Process for the preparation of imidazopyridines
PCT/EP2000/008021 WO2002014306A1 (en) 2000-08-17 2000-08-17 Process for the preparation of imidazopyridines
JP2002519456A JP2004506634A (en) 2000-08-17 2001-08-17 Method for producing imidazopyridines
DE60102478T DE60102478D1 (en) 2000-08-17 2001-08-17 PROCESS FOR THE PRODUCTION OF IMIDAZOPYRIDINES
EP01980251A EP1311509B1 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
SK101-2003A SK1012003A3 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
CZ2003321A CZ294416B6 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
AU2002212143A AU2002212143A1 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
US10/344,713 US6841679B2 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
PCT/EP2001/009519 WO2002014316A1 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
CA002417821A CA2417821A1 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines
AT01980251T ATE262526T1 (en) 2000-08-17 2001-08-17 PROCESS FOR THE PRODUCTION OF IMIDAZOPYRIDINES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2000/008021 WO2002014306A1 (en) 2000-08-17 2000-08-17 Process for the preparation of imidazopyridines

Publications (1)

Publication Number Publication Date
WO2002014306A1 true WO2002014306A1 (en) 2002-02-21

Family

ID=8164061

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2000/008021 Ceased WO2002014306A1 (en) 2000-08-17 2000-08-17 Process for the preparation of imidazopyridines
PCT/EP2001/009519 Ceased WO2002014316A1 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009519 Ceased WO2002014316A1 (en) 2000-08-17 2001-08-17 Process for the preparation of imidazopyridines

Country Status (9)

Country Link
US (1) US6841679B2 (en)
JP (1) JP2004506634A (en)
AT (1) ATE262526T1 (en)
AU (2) AU2000264428A1 (en)
CA (1) CA2417821A1 (en)
CZ (1) CZ294416B6 (en)
DE (1) DE60102478D1 (en)
SK (1) SK1012003A3 (en)
WO (2) WO2002014306A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007023504A1 (en) * 2005-08-24 2007-03-01 Elder Pharmaceuticals Ltd Process for the preparation of imidazopyridines
US7385056B2 (en) 2002-12-18 2008-06-10 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
WO2014091386A3 (en) * 2012-12-13 2014-08-07 Alembic Pharmaceuticals Limited An improved process for preparation of minodronic acid

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050563A1 (en) * 1980-10-22 1982-04-28 Synthelabo Imidazo(1,2-a)pyridine derivatives, process for their preparation and their therapeutical use
US4794185A (en) * 1986-06-27 1988-12-27 Synthelabo Process for the preparation of imidazopyridines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050563A1 (en) * 1980-10-22 1982-04-28 Synthelabo Imidazo(1,2-a)pyridine derivatives, process for their preparation and their therapeutical use
US4382938A (en) * 1980-10-22 1983-05-10 Synthelabo Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals
US4794185A (en) * 1986-06-27 1988-12-27 Synthelabo Process for the preparation of imidazopyridines

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7385056B2 (en) 2002-12-18 2008-06-10 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
WO2007023504A1 (en) * 2005-08-24 2007-03-01 Elder Pharmaceuticals Ltd Process for the preparation of imidazopyridines
US8183377B2 (en) 2005-08-24 2012-05-22 Elder Pharmaceuticals Ltd. Process for the preparation of imidazopyridines
WO2014091386A3 (en) * 2012-12-13 2014-08-07 Alembic Pharmaceuticals Limited An improved process for preparation of minodronic acid

Also Published As

Publication number Publication date
ATE262526T1 (en) 2004-04-15
US6841679B2 (en) 2005-01-11
CA2417821A1 (en) 2002-02-21
SK1012003A3 (en) 2003-07-01
AU2002212143A1 (en) 2002-02-25
JP2004506634A (en) 2004-03-04
US20040072861A1 (en) 2004-04-15
CZ294416B6 (en) 2004-12-15
DE60102478D1 (en) 2004-04-29
WO2002014316A1 (en) 2002-02-21
AU2000264428A1 (en) 2002-02-25
CZ2003321A3 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
JP5817079B2 (en) Process for preparing 6- (7-((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide, or a pharmaceutically acceptable salt thereof
JP2011511761A (en) N- {1- [3- (2-Ethoxy-5- (4-ethylpiperazinyl) sulfonylphenyl) -4,5-dihydro-5-oxo-1,2,4-triazin-6-yl] ethyl } Butyramide, its preparation method and use
US5705692A (en) Process for the preparation of iohexol
JP2010510253A5 (en)
US6841679B2 (en) Process for the preparation of imidazopyridines
KR20070113309A (en) Method for preparing 1-substituted-1H-imidazo [4,5-C] quinolin-4-amine compound and intermediate thereof
CA2391978A1 (en) Process for the preparation of sulfamides
EP1311509B1 (en) Process for the preparation of imidazopyridines
TWI613194B (en) A novel process for preparing enzalutamide
US6545149B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
EP0234514A2 (en) Pyrazolopyrimidines, intermediates thereof and processes for the preparation of them
RU2156238C2 (en) Method of synthesis of dioxoazabicyclohexanes
CN1043644C (en) Process for preparing (1H-tetrazol-5-yl)tetrazolo[1,5-a]quinoline and 1,8-naphthyridine
JP2010520158A (en) Novel process for the preparation of 3-methyl-4-phenylisoxazolo [3,4-d] pyridazin-7 (6H) -one
JPH02289563A (en) Improved process for producing ortho-carboxypyridyl- and ortho-carboxyquinolylimidazolinones
EP0812842B1 (en) Process for the preparation of 5-(alkoxymethyl)-2,3-pyridine-dicarboximide compounds
JPS6343382B2 (en)
US20030135043A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
HK1006089A (en) Process for the preparation of 5-(alkoxymethyl)-2, 3-pyridine-dicarboximide compounds
JPH10226676A (en) Aminophenyl ketone derivative and its production
JPH01246251A (en) Phenyl ether derivative
WO2004087718A1 (en) Process for the production of imidazopyridin-8-ones
WO2007104383A1 (en) Tegaserod hemimaleate and a process for its preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP